ArticleInternational journal of general medicine2026
Serum Neuritin is a Predictive Biomarker of Poor Neurological Recovery After Traumatic Spinal Cord Injury: A Prospective Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Traumatic spinal cord injury (TSCI) is a severe neurological urgency. Neuritin is a neurotrophic factor. This study aimed to explore prognostic predictive value of serum neuritin levels in TSCI. Methods: In this prospective cohort study, serum neuritin levels were quantified at admission of 126 patients and at study entry of 126 controls. The American Spinal Injury Association Impairment Scale (AIS) was used as the severity index. Poor prognosis was defined as no improvement in AIS grade at six months post TSCI versus admission. The results were analyzed using multivariate regression method. Results: Serum neuritin levels were significantly higher in patients with TSCI than in controls. No significant departure from linearity was detected between serum neuritin levels, AIS grade and poor prognosis in the restricted cubic spline. AIS grade was independently correlated with serum neuritin levels. Age, AIS grade, and serum neuritin levels were independently associated with poor prognosis. Receiver operating characteristic (ROC) curve analysis showed that poor prognosis was effectively predicted by serum neuritin levels. The results of the regression analysis were robust via sensitivity analysis, variance inflation factor estimation, the Hosmer-Lemeshow test, and Brier score calculation. The prognosis model incorporating AIS grade, age, and serum neuritin levels was visualized by nomogram, had satisfactory goodness of fit under the calibration curve, showed substantially high discrimination efficiency through the ROC curve approach, and displayed good clinical validity as demonstrated by the decision curve through internal validation. Serum neuritin levels partially mediated the association between AIS grade and poor prognosis. Conclusions: Elevated serum neuritin levels are closely associated with TSCI severity and poor prognosis following TSCI, indicating that serum neuritin may serve as a potential prognostic biomarker of TSCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.